<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920312-0152</DOCNO><DOCID>920312-0152.</DOCID><HL>   FDA Clears AIDS Drug</HL><DATE>03/12/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   I.FFI MNT</CO><MS>BASIC MATERIALS (BSC)CONGLOMERATES (CGL)CONSUMER NON-CYCLICAL (NCY)</MS><IN>CONGLOMERATES (CGL)CHEMICALS (CHM)DRUG MANUFACTURERS (DRG)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>EUROPE (EU)ITALY (ITA)NORTH AMERICA (NME)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   MILAN, Italy -- The Italian Ferruzzi-Montedison group saidWednesday that the U.S. Food and Drug Administration hasapproved Rifabutina as a Treatment Investigation New Drug.   Rifabutina was developed to prevent the infection ofacquired immune deficiency syndrome patients withmycobacterium avium complex, a lung disease similar totuberculosis that is frequently contracted by AIDS patients.The FDA status allows only for the clinical use amongpatients in life-threatening conditions.</LP><TEXT/></DOC>